Equity Line of Credit (ELOC): What It Is and Why It Dilutes

An Equity Line of Credit (ELOC) — also called a Committed Equity Facility (CEF) or Standby Equity Purchase Agreement (SEPA) — is a financing arrangement where an investor commits to purchase a specified amount of a company's shares over time, at the company's option. It's like a revolving credit line, but instead of cash backing the loan, new shares are created with each drawdown.

How an Equity Line of Credit Works

A company signs a purchase agreement with a specialized investor (usually a small institutional fund). The agreement allows the company to "put" shares to the investor at a defined discount to market price — typically 5–15% below the VWAP (volume-weighted average price) over a pricing period. The company controls when and how much to draw down, up to a total commitment amount.

Example: A company has a $10M ELOC. When they need cash, they file a notice and the investor buys $500K in shares at a 10% discount to the 5-day VWAP. The company gets the cash; the investor gets shares at a discount and typically sells them immediately, creating selling pressure.

Common ELOC Providers

A small number of specialized investment funds dominate the ELOC market for micro-cap companies. Recognizing their names in 8-K filings is a useful signal. These include (but are not limited to): Tumim Stone Capital, GEM Global Yield Fund, Keystone Capital Partners, Alumni Capital, and similar firms. When you see these names in a Securities Purchase Agreement 8-K, you're almost certainly looking at an ELOC structure.

How Dilutive Are ELOCs?

ELOCs are highly dilutive when used heavily because:

• Each drawdown creates new shares at a discount to market
• The discount means the company gets less capital per share issued than they would in a traditional offering
• ELOC investors typically sell immediately, creating regular selling pressure
• Companies in distress often draw down ELOCs frequently, accumulating significant dilution over months
• ELOC agreements often include warrants as additional compensation for the investor

SEC Filing Signals for ELOCs

• 8-K Item 1.01 — "Purchase Agreement" with a known ELOC provider is the initial signal
• S-1 or S-3 registration statement — After the purchase agreement, the company must register the shares for the ELOC investor to sell them (otherwise they're restricted). Watch for S-1 or S-3 filings naming the ELOC investor as a "selling stockholder"
• 424B3 prospectus supplement — Used for ongoing drawdowns under the registered ELOC
• 10-Q quarterly reports — Disclose total shares issued under the ELOC during the quarter and cash raised

ELOC vs ATM Program: Key Differences

Red Flags to Watch

• Company draws down repeatedly within a short timeframe — signals liquidity crisis
• ELOC capacity is very large relative to market cap (e.g., $20M ELOC on a $10M company)
• ELOC investor is a known serial ELOC provider — suggests they vetted the company as a repeat customer
• Warrants included at low strike prices — additional future dilution layer
• Company has used multiple ELOC agreements serially — signed a new one after exhausting the prior one

Deep Dive: Why ELOCs Are a Hidden Dilution Risk for Investors

Equity Lines of Credit (ELOCs) are increasingly common in the public markets, particularly among growth-oriented companies. Unlike traditional debt financing, an ELOC allows a company to draw down shares on demand — essentially creating a revolving credit facility that dilutes existing shareholders with each drawdown.

Historical Context and Regulatory Evolution

The use of ELOCs has grown significantly since the 2010s, especially in sectors like biotech, fintech, and clean energy. These instruments are often structured as "committed equity facilities" under SEC regulations, meaning the company can issue shares at prevailing market prices without further shareholder approval — a key risk factor. According to SEC EDGAR filings, companies using ELOCs typically disclose their commitment in their Form S-1 or quarterly reports, often under “Capital Structure” or “Financial Condition” sections.

Investor Implications: A Real-World Example

Take a hypothetical biotech company with 10 million shares outstanding. If it has a $50 million ELOC facility and draws down $10 million at a share price of $5, it issues 2 million new shares — diluting existing shareholders by 20%. This isn’t just about the immediate impact; it’s also about the potential for repeated drawdowns that can erode value over time. Investors using tools like our DilutionWatch or can identify companies with active ELOCs and monitor their drawdown history to better assess risk.

DilutionWatch Tools in Action

Our platform helps investors track ELOCs by parsing SEC filings for key terms like “committed equity facility” or “equity line of credit.” We flag companies with active ELOCs and provide alerts on drawdown events. For example, a recent Shelf & ATM Monitor alert revealed that a tech firm had drawn down $15 million in shares over three months, increasing its share count by 6%. This kind of granular tracking is essential for investors who want to stay ahead of dilution trends.

Related Concepts: Warrants and Shelf Registrations

Investors should also understand how ELOCs interact with other equity instruments. For instance, companies often issue warrants alongside ELOCs — a practice tracked via our Warrant Tracker. Additionally, many ELOCs are supported by shelf registrations, which allow companies to quickly raise capital without waiting for each individual offering. These mechanisms amplify the dilution risk, especially when combined with high issuance volumes or low share prices.